Tropes

www.biospectrumasia.com 2015 00322.txt.txt

#Eisai launches In-house anticancer agent in Japan Japan's leading pharmaceutical company Eisai Co. Ltd. has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg (lenvatinib mesylate, Lenvima) as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. Lenvima is the first molecular targeted treatment in Japan approved with an indication for unresectable thyroid cancer which covers differentiated thyroid cancer as well as medullary thyroid carcinoma and anaplastic thyroid carcinoma. Discovered at Eisai's Tsukuba Research Laboratories and developed in-house, Lenvima is administered an orally molecular targeted agent that selectively inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. In particular, the agent simultaneously inhibits VEGFR, FGFR and also RET which are involved especially in tumor angiogenesis and proliferation of thyroid cancer. Furthermore, Lenvima has been confirmed through X-ray co-crystal structural analysis to demonstrate a new binding mode (Type V) to VEGFR2, and exhibits rapid binding to the target molecule and potent inhibition of kinase activity, according to kinetic analysis. Lenvima was launched in the United states in February 2015, and received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in March 2015. In addition the agent is currently undergoing regulatory review in Switzerland, South korea, Canada, Singapore, Russia, Australia and Brazil l

< Back - Next >